ADVERTISEMENT

Ajanta Pharma Q1 Results Review - Robust Earnings Visibility Impart Confidence: Yes Securities

The brokerage believes margin can inch towards 30% next fiscal as healthy branded business growth and revival in U.S. would drive expansion with limited opex growth.

<div class="paragraphs"><p>(Source: Milivigerova/ pexels)</p></div>
(Source: Milivigerova/ pexels)
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
To continue reading this story
Subscribe to Unlock & Enjoy your 
Subscriber-Only
 benefits

Choose a plan

Renews automatically. Cancel anytime.
Still Not convinced ? Know More
OUR NEWSLETTERS
By signing up you agree to the Terms & Conditions of NDTV Profit